Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Moldt

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoBrian Moldt, Eva G Rakasz, Niccole Schultz, et al.
The Journal of Infectious Diseases|July 1, 2016
Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In VivoMaud Deruaz, Brian Moldt, Khoa M Le, et al.
Journal of Immunological Methods|January 4, 2011
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesMargaret E Ackerman, Brian Moldt, Richard T Wyatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyDennis R Burton, Ann J Hessell, Brandon F Keele, et al.
AIDS (London, England)|February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infectionLaurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
Plos Pathogens|April 22, 2022
HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeysBrian Moldt, Abishek Chandrashekar, Erica N Borducchi, et al.
The Journal of Infectious Diseases|April 5, 2018
Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897Qing Zhu, Bin Lu, Patrick McTamney, et al.
Transgenic Research|August 31, 2010
Pig transgenesis by Sleeping Beauty DNA transpositionJannik E Jakobsen, Juan Li, Peter M Kragh, et al.
Science Translational Medicine|May 5, 2017
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsQing Zhu, Jason S McLellan, Nicole L Kallewaard, et al.
Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoBrian Moldt, Eva G Rakasz, Niccole Schultz, et al.
The Journal of Infectious Diseases|July 1, 2016
Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In VivoMaud Deruaz, Brian Moldt, Khoa M Le, et al.
Journal of Immunological Methods|January 4, 2011
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesMargaret E Ackerman, Brian Moldt, Richard T Wyatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyDennis R Burton, Ann J Hessell, Brandon F Keele, et al.
AIDS (London, England)|February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infectionLaurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
Plos Pathogens|April 22, 2022
HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeysBrian Moldt, Abishek Chandrashekar, Erica N Borducchi, et al.
The Journal of Infectious Diseases|April 5, 2018
Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897Qing Zhu, Bin Lu, Patrick McTamney, et al.
Transgenic Research|August 31, 2010
Pig transgenesis by Sleeping Beauty DNA transpositionJannik E Jakobsen, Juan Li, Peter M Kragh, et al.
Science Translational Medicine|May 5, 2017
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsQing Zhu, Jason S McLellan, Nicole L Kallewaard, et al.
Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.
Pageof 4